The Phospho-JAK2 (Y1007/1008) Polyclonal Antibody (CABP0531) is a vital tool for researchers studying the JAK2 protein, a key player in the JAK/STAT signaling pathway involved in cell growth, survival, and differentiation. This antibody, raised in rabbits, is highly specific for phosphorylated JAK2 at tyrosine residues 1007 and 1008, making it ideal for detecting and quantifying activated JAK2 in various cell types.Phosphorylation of JAK2 at Y1007/1008 is known to activate the protein, leading to downstream signaling cascades that regulate gene expression and cellular functions. Dysregulation of JAK2 phosphorylation is implicated in various diseases, including cancer, leukemia, and myeloproliferative disorders.
By targeting phospho-JAK2, researchers can gain valuable insights into the role of JAK2 in disease pathogenesis and identify potential therapeutic targets.This antibody is validated for use in Western blot applications, enabling researchers to analyze JAK2 phosphorylation levels in cell lysates and tissue samples. Its high specificity and sensitivity make it a valuable tool for studies in oncology, hematopoiesis, and signaling pathway research. By understanding the regulation of phospho-JAK2, researchers can uncover new mechanisms of disease and develop targeted therapies for JAK2-related disorders.
This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
Purification Method:
Affinity purification
Gene ID:
3717
Storage Buffer:
Store at -20℃. Avoid freeze / thaw cycles.Buffer: PBS with 0.05% proclin300,50% glycerol,pH7.3.
Western blot analysis of lysates from C6 cells, using Phospho-JAK2-Y1007/1008 Rabbit pAb (CABP0531) at 1:400 dilution.C6 cells were treated by Pervanadate (1 mM) at 37℃ for 30 minutes after serum-starvation overnight.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit (AbGn00020).Exposure time: 60s.
